MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis

• Published in: Current controlled trials in cardiovascular medicine Vol. 20; no. 1; p. 263
• Main Authors: Uccelli, Antonio, Laroni, Alice, Brundin, Lou, Clanet, Michel, Fernandez, Oscar, Nabavi, Seyed Massood, Muraro, Paolo A, Oliveri, Roberto S, Radue, Ernst W, Sellner, Johann, Soelberg Sorensen, Per, Sormani, Maria Pia, Wuerfel, Jens Thomas, Battaglia, Mario A, Freedman, Mark S
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.05.2019; BioMed Central; BMC
• Subjects: Adolescent; Adult; Analysis; Business financing; Care and treatment; Central nervous system; Clinical trial; Clinical trials; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cross-Over Studies; Data collection; Diagnostic imaging; Disability Evaluation; Double-Blind Method; Double-blind studies; Europe; Female; Good Manufacturing Practice; Humans; Inflammation; Magnetic Resonance Imaging; Male; Medical research; Medicin och hälsovetenskap; Mesenchymal Stem Cell Transplantation - adverse effects; Mesenchymal stem cells; Mesenchymal stromal cells; Middle Aged; Multicenter Studies as Topic; Multiple sclerosis; Multiple Sclerosis - diagnostic imaging; Multiple Sclerosis - physiopathology; Multiple Sclerosis - surgery; Nonprofit organizations; Randomized Controlled Trials as Topic; Recovery of Function; Stem cell transplantation; Stem cells; Study Protocol; Time Factors; Transplantation, Autologous; Treatment Outcome; Young Adult; Europe; Italy; Spain; Mesenchymal stromal cells; Clinical trial; Multiple sclerosis; Mesenchymal stem cells
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-019-3346-z

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS. This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses. Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials. Andalusia: NCT01745783 , registered on Dec 10, 2012. Badalona: NCT02035514 EudraCT, 2010-024081-21. Registered on 2012. Canada: ClinicalTrials.gov, NCT02239393 . Registered on September 12, 2014. Copenhagen: EudraCT, 2012-000518-13 . Registered on June 21, 2012. Italy: EudraCT, 2011-001295-19, and ClinicalTrials.gov, NCT01854957 . Retrospectively registered on May 16, 2013. London: Eudra CT 2012-002357-35, and ClinicalTrials.gov, NCT01606215 . Registered on May 25, 2012. Salzburg: EudraCT, 2015-000137-78 . Registered on September 15, 2015. Stockholm: ClinicalTrials.gov, NCT01730547 . Registered on November 21, 2012. Toulouse: ClinicalTrials.gov, NCT02403947 . Registered on March 31, 2015.